New hope for rare blood vessel disease: can SHR-1703 cut steroids and stop flares?
NCT ID NCT05979051
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests a new medicine called SHR-1703 for people with EGPA, a rare disease that causes inflamed blood vessels and organ damage. The goal is to see if the drug can help patients achieve remission and reduce their daily steroid dose. About 166 adults with relapsing or hard-to-treat EGPA will take part. The approach combines the new drug with standard treatments to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.